Xenetic Biosciences, Inc. (XBIO) Lifted to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) from a hold rating to a buy rating in a research report sent to investors on Saturday morning. Zacks Investment Research currently has $3.00 target price on the stock.

According to Zacks, “Xenetic Biosciences Inc. is a biopharmaceutical company. It develops biologic drugs, oncology therapeutics and vaccinations. The Company’s proprietary drug technology platforms include PolyXen (R) for the development of next generation biologic drugs and OncoHist (R) for the development of oncology drugs focused on orphan indications. Xenetic Biosciences Inc. based in United States. “

Shares of Xenetic Biosciences (NASDAQ XBIO) opened at 2.48 on Friday. Xenetic Biosciences has a 12 month low of $2.32 and a 12 month high of $37.62. The firm has a 50-day moving average of $2.76 and a 200-day moving average of $3.40. The firm’s market cap is $21.62 million.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings results on Monday, August 14th. The company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by $0.13. On average, analysts anticipate that Xenetic Biosciences will post ($0.89) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/09/12/xenetic-biosciences-inc-xbio-lifted-to-buy-at-zacks-investment-research.html.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.

Get a free copy of the Zacks research report on Xenetic Biosciences (XBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply